12 mars 2025|
AI
|9 months agoRoche Partners with Danish Firm on Revolutionary Obesity Treatment
Basel-based Roche announces strategic partnership with Zealand Pharma to develop weekly injectable obesity treatment, marking major expansion into weight management market.
AI
Generated IllustrationKey Takeaways
AI
- Roche has entered an exclusive partnership with Danish company Zealand Pharma to develop petrelintide.
- Petrelintide is a long-acting amylin analogue currently in phase 2 clinical trials.
- Roche acquired Carmot Therapeutics in December 2023.
- Roche plans to combine petrelintide with its existing incretin asset, CT 388.
By The Numbers
+4.2%
Share price increase
$5 billion
Potential revenue
4 billion
People affected
CHF 1.9 billion
Risk-adjusted sales
They Said
"The combination could have a potential of $5 billion, despite price pressures and GLP-1 generics."
"To address the various aspects of this disease and compete effectively with multiple rivals, Roche needs to expand its therapeutic options."